EE200000685A - a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis - Google Patents

a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Info

Publication number
EE200000685A
EE200000685A EEP200000685A EEP200000685A EE200000685A EE 200000685 A EE200000685 A EE 200000685A EE P200000685 A EEP200000685 A EE P200000685A EE P200000685 A EEP200000685 A EE P200000685A EE 200000685 A EE200000685 A EE 200000685A
Authority
EE
Estonia
Prior art keywords
alpha
inhibitors
integrin receptor
tgf
beta
Prior art date
Application number
EEP200000685A
Other languages
English (en)
Inventor
Cosgrove Dominic
Original Assignee
Boys Town National Research Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boys Town National Research Hospital filed Critical Boys Town National Research Hospital
Publication of EE200000685A publication Critical patent/EE200000685A/et
Publication of EE04581B1 publication Critical patent/EE04581B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00Materials not provided for elsewhere
    • C09K3/18Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Combustion & Propulsion (AREA)
  • Materials Engineering (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200000685A 1998-05-22 1999-05-19 a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis EE04581B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8658798P 1998-05-22 1998-05-22
US8876698A 1998-06-02 1998-06-02
US15048598A 1998-09-09 1998-09-09
PCT/US1999/011073 WO1999061040A2 (en) 1998-05-22 1999-05-19 USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
EE200000685A true EE200000685A (et) 2002-04-15
EE04581B1 EE04581B1 (et) 2006-02-15

Family

ID=56289911

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000685A EE04581B1 (et) 1998-05-22 1999-05-19 a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis

Country Status (21)

Country Link
EP (1) EP1079843B1 (et)
JP (1) JP2002516287A (et)
CN (1) CN1187084C (et)
AT (1) ATE359804T1 (et)
BR (1) BR9911067A (et)
CA (1) CA2329757C (et)
CZ (1) CZ296262B6 (et)
DE (1) DE69935853T2 (et)
DK (1) DK1079843T3 (et)
EA (1) EA004145B1 (et)
EE (1) EE04581B1 (et)
ES (1) ES2285841T3 (et)
HU (1) HUP0202048A3 (et)
NO (1) NO20005883L (et)
NZ (1) NZ508317A (et)
PL (1) PL345946A1 (et)
PT (1) PT1079843E (et)
SG (1) SG117434A1 (et)
SI (1) SI1079843T1 (et)
TR (1) TR200003432T2 (et)
WO (1) WO1999061040A2 (et)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ515686A (en) 1999-06-01 2005-01-28 Biogen Inc A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
ATE325623T1 (de) * 1999-09-14 2006-06-15 Biogen Idec Inc Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
ES2398039T3 (es) * 2000-03-09 2013-03-13 Genzyme Corporation Uso de anticuerpos antagonistas anti-TGF-beta para tratar o prevenir la pérdida de función renal
KR100927670B1 (ko) 2001-04-13 2009-11-20 바이오겐 아이덱 엠에이 인코포레이티드 Vla-1에 대한 항체들
BR0315054A (pt) * 2002-11-01 2005-08-16 Boys Town Nat Res Hospital Ligando induzìvel para a integrina alfa 1 beta 1 e empregos
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
JP5496658B2 (ja) 2006-05-25 2014-05-21 バイオジェン・アイデック・エムエイ・インコーポレイテッド 脳卒中を処置する方法
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
MY173600A (en) 2012-04-25 2020-02-08 Sanofi Sa Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN104450726A (zh) * 2013-09-17 2015-03-25 深圳华大基因科技有限公司 Col4a5基因突变体及其应用
CN104212806B (zh) * 2014-07-21 2017-05-17 深圳华大基因股份有限公司 Alport综合征新的突变致病基因及其编码蛋白和应用
WO2022076452A1 (en) * 2020-10-05 2022-04-14 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Combination therapy for alport renal disease
CN112575074B (zh) * 2020-10-09 2022-12-27 中山大学 Nestin基因及蛋白在治疗器官纤维化中的应用
WO2023085396A1 (ja) * 2021-11-12 2023-05-19 Ube株式会社 アルポート症候群を治療または予防するための医薬組成物
CN114698592B (zh) * 2022-04-29 2022-11-04 中国医学科学院北京协和医院 一种干燥综合征肾损害小鼠模型的构建方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519667D0 (en) * 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition

Also Published As

Publication number Publication date
ES2285841T3 (es) 2007-11-16
NZ508317A (en) 2004-01-30
ATE359804T1 (de) 2007-05-15
CA2329757C (en) 2013-11-19
WO1999061040A2 (en) 1999-12-02
PL345946A1 (en) 2002-01-14
HUP0202048A3 (en) 2006-11-28
CZ20004358A3 (cs) 2002-01-16
WO1999061040A9 (en) 2001-02-01
PT1079843E (pt) 2007-06-26
JP2002516287A (ja) 2002-06-04
EA004145B1 (ru) 2004-02-26
DK1079843T3 (da) 2007-07-30
BR9911067A (pt) 2001-02-06
CA2329757A1 (en) 1999-12-02
CN1310625A (zh) 2001-08-29
DE69935853T2 (de) 2008-01-10
NO20005883D0 (no) 2000-11-21
CZ296262B6 (cs) 2006-02-15
HUP0202048A2 (en) 2002-10-28
NO20005883L (no) 2001-01-17
CN1187084C (zh) 2005-02-02
EA200001092A1 (ru) 2001-06-25
SG117434A1 (en) 2005-12-29
TR200003432T2 (tr) 2001-03-21
DE69935853D1 (de) 2007-05-31
WO1999061040A3 (en) 2000-01-27
EE04581B1 (et) 2006-02-15
SI1079843T1 (sl) 2007-10-31
EP1079843B1 (en) 2007-04-18
EP1079843A2 (en) 2001-03-07

Similar Documents

Publication Publication Date Title
EE200000685A (et) a1 ß1-integriiniretseptori inhibiitorite ja TGF-ß1 inhibiitorite kasutamine neeruhaiguse ravis
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
IL143901A0 (en) Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
ES2185660T3 (es) Nuevo uso de dexmedetomidina.
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
HRP20090336T1 (en) Antitumor combinations containing vegf - trap and 5fu or one of its derivatives
BRPI0415896A (pt) combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
NO980221L (no) Fremgangsmåte for behandling av tykktarmsadenomer
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
PL1703901T3 (pl) Farmaceutyczna kompozycja zawierająca alkohol 2,4-dichlorobenzylowy i amylometakrezol
YU39598A (sh) Upotreba duloksetina i njegova farmaceutska smeša
DK1152757T3 (da) MMP-inhibitorer i bindevævsblödhed
AR052015A1 (es) Agente para la profilaxis o tratamiento del sindrome metabolico
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
GB9516073D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
HC1A Change of owner name
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090519